Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Bristol-Myers Squibb Co. et al v. AstraZeneca Pharmaceuticals LP et al
Case Number:
1:22-cv-00346
Court:
Nature of Suit:
Judge:
Firms
Companies
- AstraZeneca PLC
- Bristol-Myers Squibb Co.
- Dana-Farber Cancer Institute Inc.
- Ono Pharmaceutical Co. Ltd
Sectors & Industries:
-
August 01, 2023
AstraZeneca Sets Aside $510M For Bristol-Myers Patent Deal
AstraZeneca has set aside $510 million to resolve Bristol-Myers Squibb Co.'s litigation that it infringed cancer treatment patents to create rival immunotherapy drugs, according to a recent securities filing.
-
July 31, 2023
Bristol-Myers, AstraZeneca Agree To End Drug Patent Fight
A Delaware federal judge on Monday dismissed Bristol-Myers Squibb Co.'s litigation accusing AstraZeneca of infringing cancer treatment patents to create a rival immunotherapy drug, after the pharmaceutical giants reached an agreement.
-
March 18, 2022
Bristol-Myers Sues AstraZeneca Over Cancer Drug Patents
Bristol-Myers has dragged AstraZeneca into Delaware federal court, alleging that it infringed eight Bristol-Myers cancer treatment patents to create a rival immunotherapy drug known as Imfinzi.